Processa Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
PCSA$1.95+1.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| ASSETS | ||
| Current Assets | ||
| Cash and cash equivalents | $1,191,325 | $4,706,197 |
| Prepaid expenses and other | 682,294 | 926,300 |
| Total Current Assets | 1,873,619 | 5,632,497 |
| Property and Equipment, net | 5,016 | 2,554 |
| Non-current Assets | ||
| Prepaid expenses | 1,274,442 | - |
| Total Non-current Assets | 1,274,442 | - |
| Other Assets | ||
| Operating lease right-of-use assets, net | 70,677 | 146,057 |
| Other | 5,535 | 5,535 |
| Total Other Assets | 76,212 | 151,592 |
| Total Assets | $3,229,289 | $5,786,643 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current Liabilities | ||
| Current maturities of lease liability | $73,020 | $83,649 |
| Accounts payable | 880,880 | 311,617 |
| Due to licensor | - | 189,000 |
| Due to related parties | - | 39 |
| Accrued expenses | 578,731 | 146,274 |
| Total Current Liabilities | 1,532,631 | 730,579 |
| Non-current Liabilities | ||
| Non-current lease liability | 487 | 66,905 |
| Total Liabilities | 1,533,118 | 797,484 |
| Commitments and Contingencies | - | - |
| Stockholders’ Equity | ||
| Preferred stock, par value $0.0001, 1,000,000 shares authorized; no shares issued or outstanding at December 31, 2024 or December 31, 2023 | - | - |
| Common stock, par value $0.0001, 100,000,000 shares authorized; 3,707,628 issued and 3,702,628 outstanding at December 31, 2024 and 1,291,000 issued and 1,286,000 outstanding at December 31, 2023 | 371 | 129 |
| Additional paid-in capital | 89,214,999 | 80,658,111 |
| Treasury stock, 5,000 shares | (300,000) | (300,000) |
| Accumulated deficit | (87,219,199) | (75,369,081) |
| Total Stockholders’ Equity | 1,696,171 | 4,989,159 |
| Total Liabilities and Stockholders’ Equity | $3,229,289 | $5,786,643 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.